JP2014513065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513065A5 JP2014513065A5 JP2013557757A JP2013557757A JP2014513065A5 JP 2014513065 A5 JP2014513065 A5 JP 2014513065A5 JP 2013557757 A JP2013557757 A JP 2013557757A JP 2013557757 A JP2013557757 A JP 2013557757A JP 2014513065 A5 JP2014513065 A5 JP 2014513065A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- compound
- administration
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims description 82
- 230000036470 plasma concentration Effects 0.000 claims description 24
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 231100000189 neurotoxic Toxicity 0.000 claims description 8
- 230000002887 neurotoxic effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 102100026882 Alpha-synuclein Human genes 0.000 claims description 5
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims 49
- 102000003802 alpha-Synuclein Human genes 0.000 claims 3
- 230000037396 body weight Effects 0.000 claims 3
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 206010012289 Dementia Diseases 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- YMURPRHPCWSCRF-ROPPNANJSA-N [(8bR)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl]-phenylcarbamic acid Chemical compound C1([C@](C2=C3)(C)CCN1C)N(C)C2=CC=C3N(C(O)=O)C1=CC=CC=C1 YMURPRHPCWSCRF-ROPPNANJSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/041,211 | 2011-03-04 | ||
| US13/041,211 US20120225922A1 (en) | 2011-03-04 | 2011-03-04 | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| PCT/US2012/026984 WO2012154285A1 (en) | 2011-03-04 | 2012-02-28 | Effective amounts of (3ar)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231910A Division JP2018076332A (ja) | 2011-03-04 | 2017-12-01 | （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014513065A JP2014513065A (ja) | 2014-05-29 |
| JP2014513065A5 true JP2014513065A5 (OSRAM) | 2015-04-09 |
Family
ID=46753679
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013557757A Withdrawn JP2014513065A (ja) | 2011-03-04 | 2012-02-28 | （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法 |
| JP2017231910A Pending JP2018076332A (ja) | 2011-03-04 | 2017-12-01 | （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017231910A Pending JP2018076332A (ja) | 2011-03-04 | 2017-12-01 | （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (9) | US20120225922A1 (OSRAM) |
| EP (1) | EP2683242B8 (OSRAM) |
| JP (2) | JP2014513065A (OSRAM) |
| KR (1) | KR20140019361A (OSRAM) |
| CN (1) | CN103582419A (OSRAM) |
| AU (1) | AU2012254093B2 (OSRAM) |
| BR (1) | BR112013022673A2 (OSRAM) |
| CA (1) | CA2829039C (OSRAM) |
| DK (1) | DK2683242T3 (OSRAM) |
| WO (1) | WO2012154285A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120225922A1 (en) * | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| CA2994974C (en) * | 2015-08-14 | 2024-04-09 | Qr Pharma | Methods of treatment or prevention of acute brain or nerve injuries |
| WO2018217892A1 (en) * | 2017-05-24 | 2018-11-29 | Qr Pharma, Inc. | Prevention or treatment of disease states due to metal dis-homeostasis via administration of posiphen to healthy or sick humans |
| WO2020061404A1 (en) * | 2018-09-21 | 2020-03-26 | Aristea Translational Medicine Corporation | Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions |
| BR112021007476A2 (pt) | 2018-11-21 | 2021-11-03 | Ionis Pharmaceuticals Inc | Compostos e métodos para reduzir a expressão de príon |
| WO2021067864A1 (en) * | 2019-10-02 | 2021-04-08 | Sangamo Therapeutics, Inc. | Zinc finger protein transcription factors for treatment of prion disease |
| US20220370412A1 (en) * | 2021-05-18 | 2022-11-24 | Annovis Bio, Inc. | Inhibition of neurological injuries due to infections via administration of butanetap and analogs thereof |
| WO2023164696A2 (en) * | 2022-02-28 | 2023-08-31 | Ionis Pharmaceuticals, Inc. | Rnai agents of prion expression |
| EP4629980A1 (en) * | 2022-12-06 | 2025-10-15 | SRI International | Antimicrobial compounds |
| WO2024263878A2 (en) * | 2023-06-21 | 2024-12-26 | Annovis Bio, Inc. | Solid forms of posiphen d-tartrate |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171750A (en) | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
| US5409948A (en) * | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| HUP0003852A3 (en) | 1997-07-09 | 2003-04-28 | Nat Inst Of Health Rockville | Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias |
| ATE345803T1 (de) | 2000-03-03 | 2006-12-15 | Eisai Co Ltd | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| CA2465534C (en) | 2000-11-02 | 2009-10-27 | Nigel H. Greig | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof |
| WO2003024450A1 (en) * | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| US6495700B1 (en) | 2002-01-09 | 2002-12-17 | Axonyx, Inc. | Process for producing phenserine and its analog |
| US20040024043A1 (en) * | 2002-03-22 | 2004-02-05 | Nigel Greig | Method for treating cognitive disorders |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| EP1617844A4 (en) | 2003-04-03 | 2009-07-22 | Prana Biotechnology Ltd | TREATMENT OF NEUROLOGICAL DISEASES |
| US20050013869A1 (en) * | 2003-07-18 | 2005-01-20 | Chaw Cheng Shu | Sustained release formulation for carbamates and a method therefor |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| WO2005089746A1 (en) * | 2004-03-19 | 2005-09-29 | Axonyx, Inc. | Dosage titration for treatment of cognitive disorders |
| WO2005091987A2 (en) | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Method of treating down syndrome |
| CA2509265A1 (en) * | 2004-06-08 | 2005-12-08 | Axonyx, Inc. | Methods of delaying alzheimer's disease progression using a beta-amyloid precursor protein inhibitor and hmg coa reductase inhibitor |
| US20060160852A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
| US7858803B2 (en) | 2007-04-27 | 2010-12-28 | The General Hospital Corporation | Imaging tracers for early detection and treatment of amyloid plaques caused by Alzheimer's disease and related disorders |
| AU2008262438A1 (en) * | 2007-06-07 | 2008-12-18 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastroesophageal reflux disease |
| JP4690362B2 (ja) * | 2007-07-04 | 2011-06-01 | 株式会社リコー | Ｓｉｍｄ型マイクロプロセッサおよびｓｉｍｄ型マイクロプロセッサのデータ転送方法 |
| WO2010117727A2 (en) * | 2009-03-30 | 2010-10-14 | The General Hospital Corporation | Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions |
| US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
-
2011
- 2011-03-04 US US13/041,211 patent/US20120225922A1/en not_active Abandoned
-
2012
- 2012-02-28 JP JP2013557757A patent/JP2014513065A/ja not_active Withdrawn
- 2012-02-28 DK DK12782326.8T patent/DK2683242T3/da active
- 2012-02-28 AU AU2012254093A patent/AU2012254093B2/en active Active
- 2012-02-28 BR BR112013022673A patent/BR112013022673A2/pt not_active IP Right Cessation
- 2012-02-28 KR KR1020137025992A patent/KR20140019361A/ko not_active Ceased
- 2012-02-28 CA CA2829039A patent/CA2829039C/en active Active
- 2012-02-28 EP EP12782326.8A patent/EP2683242B8/en active Active
- 2012-02-28 WO PCT/US2012/026984 patent/WO2012154285A1/en not_active Ceased
- 2012-02-28 CN CN201280021686.1A patent/CN103582419A/zh active Pending
-
2015
- 2015-06-30 US US14/755,322 patent/US20150374664A1/en not_active Abandoned
-
2017
- 2017-03-06 US US15/450,937 patent/US10383851B2/en active Active
- 2017-12-01 JP JP2017231910A patent/JP2018076332A/ja active Pending
-
2019
- 2019-07-08 US US16/504,813 patent/US11096926B2/en active Active
-
2020
- 2020-08-17 US US16/994,921 patent/US11376238B2/en active Active
- 2020-08-17 US US16/994,924 patent/US11382893B2/en active Active
- 2020-08-17 US US16/994,881 patent/US11400075B2/en active Active
-
2022
- 2022-06-07 US US17/834,367 patent/US12144798B2/en active Active
-
2024
- 2024-10-13 US US18/914,189 patent/US20250114330A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513065A5 (OSRAM) | ||
| JP2014528914A5 (OSRAM) | ||
| JP2014517050A5 (OSRAM) | ||
| NZ751418A (en) | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | |
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| GB201104267D0 (en) | Pyrrolopyridineamino derivatives | |
| BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
| HK1247093A1 (zh) | 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法 | |
| NZ598137A (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| WO2015191506A3 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| JP2009533356A5 (OSRAM) | ||
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| JP2012111764A5 (OSRAM) | ||
| WO2014070991A3 (en) | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| FI3865484T3 (fi) | Pde9:n estäjä, jossa on imidatsopyratsinonirunko, perifeeristen sairauksien hoitoon | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2015535247A5 (OSRAM) | ||
| JP2015522018A5 (OSRAM) | ||
| PH12013501098A1 (en) | Pharmaceutical compositions | |
| KR20140025461A (ko) | 진행성 고형 종양의 치료 방법 | |
| JP2011518168A5 (OSRAM) |